Compare Coupang Inc (CPNG) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coupang Inc vs Zimmer Biomet Holdings Inc — how do they compare? Coupang Inc trades at $15.82 (market cap $27.70B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Coupang Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Coupang Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Coupang Inc for 55 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| CPNG | ZBH | |
|---|---|---|
Market Cap | $27.70B | $16.95B |
Volume | 27,703,608 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $32.47 | $103.98 |
52-Week Low | $13.75 | $79.58 |
Typical Hold Time | 55 Days | 89 Days |
Enterprise Value | $27.22B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coupang (CPNG) trades at $15.82, up 6.82% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical outlook with positive moving averages and institutional support. Revenue growth remains robust at $34.53 billion for 2025, though profitability metrics show challenges with negative net income margin and ROE. Analyst consensus is strongly bullish with 87.5% buy ratings and a $25.25 price target, representing significant upside potential from current levels.
The investment case hinges on Coupang's dominant South Korean market position and expanding logistics network, but faces headwinds from inconsistent profitability and competitive pressures. While valuation appears reasonable on sales (P/S 0.8), high P/E ratio reflects earnings volatility. Key risks include execution challenges in international expansion and margin pressure from logistics investments. The stock offers growth exposure but requires careful monitoring of profitability trends.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coupang Inc
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
